Further!The IPO IPO of the Customs Cross Customs Customs Crossing Instrument was asked by the Shanghai Stock Exchange

On July 20, 2022, Beijing Langshi Instrument Co., Ltd. (hereinafter referred to as the "Langshi Instrument") sprint science and technology board was asked by the Shanghai Stock Exchange.

Picture source: Shanghai Stock Exchange official website

Langshi Instrument is a high -tech company that provides advanced medical imaging products and services. It is mainly engaged in the research and development, production, sales and services of professional medical imaging equipment. It has formed a series of core technologies around cone -shaped beam CT imaging technology.

Financial data shows that the company's revenue in 2019, 2020, and 2021 was 222 million yuan, 215 million yuan, and 405 million yuan, respectively; the corresponding net profit corresponding to the mother was RMB 2,044,900, RMB 1,810,400, and 64.1889 million yuan, respectively.

The company's selection of the (1) set of Article 2.1.2 of the "Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules": "The estimated market value is expected to be less than RMB 1 billion, and the net profit in the past two years is positive and cumulative net profit It is no less than RMB 50 million, or the estimated market value is not less than RMB 1 billion, and the net profit in the past year is positive and operating income is not less than RMB 100 million. "

According to the "Analysis Report for Market value" issued by the sponsorship agency, the issuer is expected to issue a market value of not less than 1 billion yuan; according to the "Audit Report" issued by Tianjian accountant (Tianjian Council [2022] No. 5248), the issuer 2020 And the net profit in 2021 (calculated by deducting the low before and after the deduction of non -recurring profit and loss) was RMB 10.2288 million and 567.77 million yuan, respectively. The net profit in the past two years was positive and the cumulative net profit was not less than RMB 50 million. The issuer meets the aforementioned listing standards.

This time it is planned to raise funds for medical cone beam CT (Haining) production base construction project, R & D center construction project, and marketing network construction project.

As of the date of the signing of this prospectus, Qian Zhiming directly held 33.80%of the company's shares, and at the same time, as a limited partner, he held a 3.94%contribution share of Haining Hairui, and was the company's controlling shareholder and actual controller.

- END -